|
(Health-NewsWire.Net, July 22, 2015 ) Major Depressive Disorder - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Major Depressive Disorder - Pipeline Review, H1 2015” which provides an overview of the Major Depressive Disorder therapeutic pipeline.
This report gives thorough data on the helpful advancement for Major Depressive Disorder, complete with relative investigation at different stages, therapeutics appraisal by medication target, system of activity (MoA), course of organization (RoA) and particle sort, alongside most recent redesigns, and included news and press discharges. It likewise surveys key players included in the remedial improvement for Major Depressive Disorder and exceptional components on late-stage and ended undertakings.
The report upgrades choice making abilities and help to make compelling counter methods to increase upper hand. It reinforces R&D pipelines by recognizing new targets and MOAs to deliver first-in-class and best-in-class items.
Complete report on H1, 2015 Pipeline Review of “Major Depressive Disorder” addition with 68 market data tables and 15 figures, spread across 201 pages is http://www.rnrmarketresearch.com/major-depressive-disorder-pipeline-review-h1-2015-market-report.html .
This report highlights investigational medications from crosswise over globe covering more than 20 treatment zones and almost 3,000 evidences. The report is fabricated utilizing information and data sourced from Global Markets Direct's exclusive databases, Company/University sites, SEC filings, financial specialist presentations and included press discharges from organization/college locales and industry-particular outsider sources, set up together by Global Markets Direct's group. Medication profiles/records included in the report experiences intermittent updation taking after a stringent arrangement of procedures that guarantees that every one of the profiles are redesigned with the most recent arrangement of data. Also, procedures including live news & arrangements following, program based ready box and clinical trials registries following guarantee that the latest improvements are caught on a constant premise.
Companies Discussed/Mentioned in this Research:
Actavis plc, Alkermes Plc, Angelini Group, Azevan Pharmaceuticals, Inc., BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., e-Therapeutics plc, Edgemont Pharmaceuticals, LLC, Eli Lilly and Company, Euthymics Bioscience, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, H. Lundbeck A/S, Hua Medicine Ltd., Intas Pharmaceuticals Ltd., Intra-Cellular Therapies, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, Lead Discovery Center GmbH, Luye Pharma Group Ltd., Methylation Sciences Inc., miCure Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Naurex, Inc., Neuralstem, Inc., nLife Therapeutics, S.L., Otsuka Holdings Co., Ltd., Pherin Pharmaceuticals, Inc., Reviva Pharmaceuticals Inc., Richter Gedeon Nyrt., Saniona AB, Sumitomo Dainippon Pharma Co., Ltd., Sunovion Pharmaceuticals Inc., Suven Life Sciences Ltd., Trevena, Inc. and VistaGen Therapeutics , Inc.
Drugs Profile Discussed in this Research :
(aripiprazole + sertraline), (samidorphan + buprenorphine hydrochloride), amitifadine, AN-788, aripiprazole, AV-101, AVP-786, basimglurant, brexpiprazole, bupropion hydrochloride ER, cariprazine, CERC-301, desvenlafaxine succinate SR, EDG-005, edivoxetine, esketamine hydrochloride, INASTR-001, ITI-007, lurasidone hydrochloride, LY-03005, LY-2940094, MIN-117, miR-135, MSI-195, NLF-NEU, NRX-1074, NSI-189, onabotulinumtoxin A, PH-10, rapastinel, RP-5063, SEP-363856, Small Molecule to Inhibit FKBP51 for Major Depressive Disorder, Small Molecule to Target SLC6A15 for Major Depressive Disorder, Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders, Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder, Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System, Small Molecules to Antagonize NR2B for Major Depression, Small Molecules to Inhibit COMT for Cognitive Disorders, SRX-246, SUVN-911, tedatioxetine, tramadol hydrochloride, trazodone hydrochloride, TRV-250 and vortioxetine hydrobromide
Inquire for discount on this report http://www.rnrmarketresearch.com/contacts/discount?rname=395198 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Mental Illness Drugs Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
